Tezepelumab-ekko - Biologic Drug Details

Summary for tezepelumab-ekko

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for tezepelumab-ekko

Mechanism of Action	Thymic Stromal Lymphopoietin Blockers
Established Pharmacologic Class	Thymic Stromal Lymphopoietin Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tezepelumab-ekko Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tezepelumab-ekko Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tezepelumab-ekko Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Tezepelumab-ekko

Last updated: February 24, 2026

What is the Market Position of Tezepelumab-ekko?

Tezepelumab-ekko (brand name: Tezspire) is a monoclonal antibody developed by AstraZeneca, approved in December 2021 by the FDA for severe asthma. It offers an innovative approach by targeting thymic stromal lymphopoietin (TSLP), an upstream cytokine involved in asthma inflammation pathways.

As of 2023, it is positioned as a first-in-class biologic for severe asthma with broad indications across multiple patient subgroups. Its mechanism allows efficacy regardless of eosinophil levels, expanding its potential market share over existing biologics like dupilumab or mepolizumab.

How Does the Market Evolve?

Market Size and Growth Rate

• The global severe asthma biologics market is valued at approximately USD 6.8 billion in 2022.
• Projected compound annual growth rate (CAGR) for this market stands at roughly 11% from 2023 to 2030 [1].

Key Drivers

• Increasing prevalence of asthma and severe asthma globally.
• Unmet medical needs for patients inadequately controlled by corticosteroids.
• Growing preference for targeted biologic therapies over traditional corticosteroids and bronchodilators.
• Expansion of indications to include chronic rhinosinusitis with nasal polyps (CRSwNP), which is in development.

Competitive Landscape

Biologic	Target	Approved Indications	Market Share (2022)	Key Competitors
Tezepelumab-ekko	TSLP	Severe asthma	Emerging	Mepolizumab, Dupilumab, Benralizumab
Mepolizumab	IL-5	Eosinophilic asthma	35%	Reslizumab, Benralizumab
Dupilumab	IL-4/13	Eosinophilic and allergic asthma	30%	Mepolizumab, Reslizumab

Clinical and Regulatory Milestones

• FDA approval in December 2021.
• European Medicines Agency (EMA) approval in early 2022.
• Phase 3 trials for indications like CRSwNP ongoing, with potential FDA submission in 2024.

What is the Financial Outlook?

Revenue Projections

• AstraZeneca forecasted USD 300 million in sales globally in 2023.
• Revenue is expected to reach USD 1 billion by 2025, driven by market expansion and new indications.
• Peak sales estimates range from USD 2.5 billion to USD 3 billion by 2030, contingent on market penetration and competitive dynamics.

Cost and Pricing

• List price in the U.S. approximates USD 30,000 per year per patient.
• Payment models may include value-based agreements emphasizing improved disease control and reduced hospitalizations.
• R&D investments are estimated at USD 1.2 billion through clinical development and commercialization.

Market Penetration Strategy

• Focus on pulmonology and allergy specialists.
• Launching in key markets: U.S., EU, Japan.
• Partnerships and formulary inclusion efforts with payers.

Risks and Challenges

• Competition from established biologics targeting eosinophil and IL-4/13 pathways.
• Pricing pressures from payers.
• Delays in label expansion for new indications or approvals.
• Potential biosimilar entry after patent expiry, estimated around 2030.

Patent Landscape and Intellectual Property

• Patent protection granted through 2030 for core formulations.
• Additional patents covering methods of use, combination therapies, and manufacturing processes extend protection to 2035.
• Patent challenges may emerge, particularly in jurisdictions with compulsory licensing provisions.

Conclusion

Tezepelumab-ekko is poised to grow rapidly within the severe asthma biologics market, targeting a broad patient subgroup with upstream cytokine inhibition. Revenue growth will depend on successful market penetration, competitive positioning, and expansion into other indications. The upcoming clinical milestones and patent protections will influence its long-term financial trajectory.

---

Key Takeaways

• Tezepelumab-ekko holds a strategic position as a first-in-class TSLP inhibitor for severe asthma.
• The severe asthma biologics market is expanding at 11% CAGR, with peak sales potential around USD 3 billion.
• Revenue projections for AstraZeneca suggest rapid growth, supported by broad indications and market penetration.
• Competition from existing biologics and payer dynamics pose significant challenges.
• Patent protections extend into the mid-2030s, with future biosimilar threats possible post-2030.

FAQs

1. What differentiates tezepelumab-ekko from other biologics for asthma?

   • It targets TSLP upstream cytokine, modulating multiple inflammatory pathways and applicable regardless of eosinophil status.

2. When is tezepelumab-ekko expected to expand into additional indications?

   • Clinical trials for CRSwNP are ongoing, with submission expected in 2024.

3. How does pricing compare to other biologics?

   • The list price in the U.S. is approximately USD 30,000 annually per patient, similar to other monoclonal antibodies.

4. Will biosimilars threaten tezepelumab-ekko's market share?

   • Patent expiry around 2030 could open avenues for biosimilars, but current patent protections extend into the 2030s.

5. In which regions is tezepelumab-ekko most likely to see the fastest growth?

   • U.S., European Union, and Japan, driven by approved indications and payer support.

---

References

[1] MarketResearch.com. (2023). Global severe asthma biologics market forecast.
[2] AstraZeneca. (2022). Tezspire (tezepelumab-ekko) prescribing information.
[3] Euromonitor International. (2023). Biologics for respiratory diseases overview.